Want to see HK:1877 full AI Analyst Report?
1877 Stock Chart & Stats
HK$27.54
-HK$0.08(-0.74%)
At close: 4:00 PM EST
HK$27.54
-HK$0.08(-0.74%)
Day’s Range― - ―
52-Week RangeHK$15.25 - HK$30.80
Previous CloseN/A
Volume306.00K
Average Volume (3M)1.70M
Market Cap
HK$31.14B
Enterprise ValueHK$19.88B
Total Cash (Recent Filing)HK$3.70B
Total Debt (Recent Filing)HK$5.91B
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding260,295,700
10 Day Avg. Volume1,152,090
30 Day Avg. Volume1,695,639
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)3.19
Price to Sales (P/S)7.92
P/FCF Ratio-15.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$25.65Price Target Upside-6.87% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.26
Revenue Forecast (FY)HK$3.37B
Bulls Say, Bears Say
Bulls Say
Improving RevenueSustained revenue growth indicates improving demand and commercial traction across the company’s product portfolio. If this trend continues, a larger revenue base can support operating leverage, broader investment in the pipeline, and a clearer path toward eventual profitability.
Strong Gross MarginsVery high gross margins show that commercialized products generate substantial value after direct product costs. This provides an attractive foundation for future earnings improvement, although the company must still control operating expenses and convert product-level economics into sustainable net income.
Meaningful Asset And Equity BaseThe sizeable asset base and remaining equity provide some financial cushion for ongoing development and commercialization activities. This balance-sheet resource base can support strategic investment and help absorb operating volatility, even though its effectiveness is reduced by losses and rising leverage.
Bears Say
Ongoing LossesPersistent net losses show that strong product-level margins have not yet translated into company-wide profitability. Continued losses can constrain internally funded growth, weaken returns on equity, and make the business more dependent on successful commercialization or additional financing.
Substantial Cash BurnNegative operating and deeply negative free cash flow indicate that current operations and investment require substantial cash outflows. This reduces financial flexibility, increases reliance on external funding or existing balance-sheet resources, and could limit the pace of pipeline development if burn persists.
Rising LeverageThe sharp increase in debt relative to equity represents a materially heavier balance-sheet burden than in 2022. Higher leverage can restrict capital allocation flexibility and increase pressure on the company to improve earnings and cash generation while maintaining development and commercialization spending.
Shanghai Junshi Biosciences Co., Ltd. Class H News
1877 FAQ
What was Shanghai Junshi Biosciences Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Junshi Biosciences Co., Ltd. Class H lowest stock price was HK$15.25 and its highest was HK$30.80 in the past 12 months.
What is Shanghai Junshi Biosciences Co., Ltd. Class H’s market cap?
Shanghai Junshi Biosciences Co., Ltd. Class H’s market cap is HK$31.14B.
When is Shanghai Junshi Biosciences Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Junshi Biosciences Co., Ltd. Class H’s upcoming earnings report date is Oct 29, 2026 which is in 10 days.
How were Shanghai Junshi Biosciences Co., Ltd. Class H’s earnings last quarter?
Shanghai Junshi Biosciences Co., Ltd. Class H released its earnings results on Aug 26, 2026. The company reported HK$0.023 earnings per share for the quarter.
Is Shanghai Junshi Biosciences Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Junshi Biosciences Co., Ltd. Class H’s price is currently Overvalued.
Does Shanghai Junshi Biosciences Co., Ltd. Class H pay dividends?
Shanghai Junshi Biosciences Co., Ltd. Class H does not currently pay dividends.
What is Shanghai Junshi Biosciences Co., Ltd. Class H’s EPS estimate?
Shanghai Junshi Biosciences Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Junshi Biosciences Co., Ltd. Class H have?
Shanghai Junshi Biosciences Co., Ltd. Class H has 260,295,700 shares outstanding.
What happened to Shanghai Junshi Biosciences Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Junshi Biosciences Co., Ltd. Class H reported an EPS of HK$0.023 in its last earnings report. Following the earnings report the stock price went up 2.201%.
Which hedge fund is a major shareholder of Shanghai Junshi Biosciences Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:1877
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Junshi Biosciences Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$25.65 (-6.87% Downside)
HK$25.65 (-6.87% Downside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.95%
12-Months-Change
Fundamentals
Return on Equity
-7.32%
Trailing 12-Months
Asset Growth
28.51%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical firm focused on the research, creation, and marketing of diverse pharmaceutical products. Operating within the People's Republic of China, its therapeutic focus spans oncology, metabolic disorders, autoimmune conditions, neurological ailments, and infectious diseases. Among its offerings is JS001, marketed as TUOYI, a recombinant humanized anti-PD-1 monoclonal antibody. This treatment is prescribed for a wide array of cancers, including melanoma (both cutaneous and mucosal), soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. The company's development pipeline also includes UBP1211, a biosimilar version of Humira, intended for rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Additionally, they are advancing JS002, a recombinant humanized anti-PCSK9 monoclonal antibody designed to address hyperlipidemia, and UBP1213, an injectable recombinant humanized anti-BLyS monoclonal antibody. Further projects encompass JS501, a biosimilar of Avastin; JS003, an injectable recombinant humanized anti-PD-L1 monoclonal antibody; JS101, which acts as a pan-CDK inhibitor; TAB004/JS004, an injectable recombinant humanized anti-BTLA monoclonal antibody; and JS005, another injectable recombinant humanized anti-IL-17A monoclonal antibody. Furthermore, Junshi Biosciences holds partnerships, including an agreement with Eli Lilly and Company to collaboratively develop therapeutic antibodies aimed at the prevention and treatment of COVID-19, the illness resulting from the SARS-CoV-2 novel coronavirus. Another collaboration is with Coherus Biosciences, Inc. for the advancement and commercialization of toripalimab, which is Junshi Biosciences' anti-PD-1 antibody. Established in 2012, Shanghai Junshi Biosciences Co., Ltd. maintains its primary offices in Shanghai, People's Republic of China.
1877 Stock 12 Month Forecast
Average Price Target
HK$25.65
▼(-6.87% Downside)
Technical Analysis
Innovent Biologics
―
Zai Lab Ltd
―
Akeso, Inc.
―
RemeGen Co. Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―